Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
25.55
-0.32 (-1.24%)
Jun 29, 2026, 4:00 PM EDT - Market closed
Zenas BioPharma Revenue
In the year 2025, Zenas BioPharma had annual revenue of $10.00M with 100.00% growth.
Revenue (ttm)
$10.00M
Revenue Growth
+100.00%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
167
Market Cap
1.61B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.00M | 5.00M | 100.00% |
| Dec 31, 2024 | 5.00M | -45.00M | -90.00% |
| Dec 31, 2023 | 50.00M | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionZBIO News
- 12 days ago - Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 15 days ago - Zenas BioPharma Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference - Transcripts
- 18 days ago - Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit - GlobeNewsWire
- 27 days ago - Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine - GlobeNewsWire
- 4 weeks ago - Zenas BioPharma Slides: Corporate presentation - Filings
- 4 weeks ago - Zenas BioPharma submits BLA to FDA for obexelimab - TheFly
- 4 weeks ago - Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD - GlobeNewsWire
- 5 weeks ago - Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress - GlobeNewsWire